1
|
Pherez-Farah A, López-Sánchez RDC, Villela-Martínez LM, Ortiz-López R, Beltrán BE, Hernández-Hernández JA. Sphingolipids and Lymphomas: A Double-Edged Sword. Cancers (Basel) 2022; 14:2051. [PMID: 35565181 PMCID: PMC9104519 DOI: 10.3390/cancers14092051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2022] [Accepted: 04/14/2022] [Indexed: 11/24/2022] Open
Abstract
Lymphomas are a highly heterogeneous group of hematological neoplasms. Given their ethiopathogenic complexity, their classification and management can become difficult tasks; therefore, new approaches are continuously being sought. Metabolic reprogramming at the lipid level is a hot topic in cancer research, and sphingolipidomics has gained particular focus in this area due to the bioactive nature of molecules such as sphingoid bases, sphingosine-1-phosphate, ceramides, sphingomyelin, cerebrosides, globosides, and gangliosides. Sphingolipid metabolism has become especially exciting because they are involved in virtually every cellular process through an extremely intricate metabolic web; in fact, no two sphingolipids share the same fate. Unsurprisingly, a disruption at this level is a recurrent mechanism in lymphomagenesis, dissemination, and chemoresistance, which means potential biomarkers and therapeutical targets might be hiding within these pathways. Many comprehensive reviews describing their role in cancer exist, but because most research has been conducted in solid malignancies, evidence in lymphomagenesis is somewhat limited. In this review, we summarize key aspects of sphingolipid biochemistry and discuss their known impact in cancer biology, with a particular focus on lymphomas and possible therapeutical strategies against them.
Collapse
Affiliation(s)
- Alfredo Pherez-Farah
- Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Nuevo Leon, Mexico
| | | | - Luis Mario Villela-Martínez
- Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán Rosales 80030, Sinaloa, Mexico
- Hospital Fernando Ocaranza, ISSSTE, Hermosillo 83190, Sonora, Mexico
- Centro Médico Dr. Ignacio Chávez, ISSSTESON, Hermosillo 83000, Sonora, Mexico
| | - Rocío Ortiz-López
- Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Monterrey 64710, Nuevo Leon, Mexico
| | - Brady E Beltrán
- Hospital Edgardo Rebagliati Martins, Lima 15072, Peru
- Instituto de Investigaciones en Ciencias Biomédicas, Universidad Ricardo Palma, Lima 1801, Peru
| | | |
Collapse
|
2
|
Latour S, Zanese M, Le Morvan V, Vacher AM, Menard N, Bijou F, Durrieu F, Soubeyran P, Savina A, Vacher P, Bresson-Bepoldin L. Role of Calcium Signaling in GA101-Induced Cell Death in Malignant Human B Cells. Cancers (Basel) 2019; 11:cancers11030291. [PMID: 30832225 PMCID: PMC6468563 DOI: 10.3390/cancers11030291] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Revised: 02/15/2019] [Accepted: 02/22/2019] [Indexed: 12/12/2022] Open
Abstract
GA101/obinutuzumab is a novel type II anti-CD20 monoclonal antibody (mAb), which is more effective than rituximab (RTX) in preclinical and clinical studies when used in combination with chemotherapy. Ca2+ signaling was shown to play a role in RTX-induced cell death. This report concerns the effect of GA101 on Ca2+ signaling and its involvement in the direct cell death induced by GA101. We reveal that GA101 triggered an intracellular Ca2+ increase by mobilizing intracellular Ca2+ stores and activating Orai1-dependent Ca2+ influx in non-Hodgkin lymphoma cell lines and primary B-Cell Chronic Lymphocytic Leukemia (B-CLL) cells. According to the cell type, Ca2+ was mobilized from two distinct intracellular compartments. In Raji, BL2, and B-CLL cells, GA101 induced a Ca2+ release from lysosomes, leading to the subsequent lysosomal membrane permeabilization and cell death. Inhibition of this calcium signaling reduced GA101-induced cell death in these cells. In SU-DHL-4 cells, GA101 mobilized Ca2+ from the endoplasmic reticulum (ER). Inhibition of ER replenishment, by blocking Orai1-dependent Ca2+ influx, led to an ER stress and unfolded protein response (UPR) which sensitized these cells to GA101-induced cell death. These results revealed the central role of Ca2+ signaling in GA101’s action mechanism, which may contribute to designing new rational drug combinations improving its clinical efficacy.
Collapse
Affiliation(s)
- Simon Latour
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Marion Zanese
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Valérie Le Morvan
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Anne-Marie Vacher
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Nelly Menard
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Fontanet Bijou
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
| | - Francoise Durrieu
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
| | - Pierre Soubeyran
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Ariel Savina
- Institut Roche, 92100 Boulogne-Billancourt, France.
| | - Pierre Vacher
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| | - Laurence Bresson-Bepoldin
- Institut Bergonié, Comprehensive Cancer Centre, F-33000 Bordeaux, France.
- Department of Life and Health Sciences, University of Bordeaux, F-33076 Bordeaux, France.
- INSERM, U1218 ACTION, F-33000 Bordeaux, France.
| |
Collapse
|
3
|
Zhang F, Yang J, Li H, Liu M, Zhang J, Zhao L, Wang L, LingHu R, Feng F, Gao X, Dong B, Liu X, Zi J, Zhang W, Hu Y, Pan J, Tian L, Hu Y, Han Z, Zhang H, Wang X, Zhao L. Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization. Oncoimmunology 2016; 5:e1143995. [PMID: 27467962 DOI: 10.1080/2162402x.2016.1143995] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2015] [Revised: 01/12/2016] [Accepted: 01/13/2016] [Indexed: 12/31/2022] Open
Abstract
Despite the success of CD20 antibody rituximab in immunotherapy, acquired resistance is one of the prime obstacles for the successful treatment of B-cell malignancies. There is an urgent need to intensify efforts against resistance in cancer treatment. Growing evidence indicated that lysosomes may form an "Achilles heel" for cancer cells by sensitizing them to death pathways. Here, we uncover an important role of CD20 in initiation of ceramide/lysosomal membrane permeabilization (LMP)-mediated cell death, showing that colocalization of CD20-TNFR1 after type II CD20 antibody ligation can stimulate de novo ceramide synthesis by ceramide synthase and consequently induce remarkable lysosomal permeabilization (LMP) and lysosome-mediated cell death. Further studies show that the potent lysosome-mediated cell death induced by CD20 antibodies exhibits a profound killing effect against both rituximab-sensitive and -resistant (RR) lymphoma. Furthermore, engineering of rituximab by introducing a point mutation endows it with the ability to induce potent ceramide/LMP-mediated cell death in both RR lymphoma and primary B-cell malignancies from patients with rituximab-refractory, suggesting the potential clinical application to combat rituximab resistance.
Collapse
Affiliation(s)
- Fan Zhang
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University , Shanghai, People's Republic of China
| | - Junlan Yang
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University , Shanghai, People's Republic of China
| | - Huafei Li
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University , Shanghai, People's Republic of China
| | - Moyan Liu
- Department of Nephrology, General Hospital of Jinan Military Command , Jinan, People's Republic of China
| | - Jie Zhang
- Nursing Department, PLA General Hospital, PLA School of Medicine , Beijing, People's Republic of China
| | - Lichao Zhao
- Medical Department, General Hospital of Jinan Military Command , Jinan, China
| | - Lingxiong Wang
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University , Shanghai, People's Republic of China
| | - RuiXia LingHu
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Fan Feng
- Department of Pharmacy, General Hospital of Shenyang Military Command , Shenyang, People's Republic of China
| | - Xudong Gao
- Department of Gastroenterology, PLA 302 Hospital , Beijing, People's Republic of China
| | - Biqin Dong
- Department of Physics, Key Laboratory of Micro and Nano Photonic Structures (Ministry of Education) , and Key Laboratory of Surface Physics, Fudan University , Shanghai, People's Republic of China
| | - Xiaohan Liu
- Department of Physics, Key Laboratory of Micro and Nano Photonic Structures (Ministry of Education) , and Key Laboratory of Surface Physics, Fudan University , Shanghai, People's Republic of China
| | - Jian Zi
- Department of Physics, Key Laboratory of Micro and Nano Photonic Structures (Ministry of Education) , and Key Laboratory of Surface Physics, Fudan University , Shanghai, People's Republic of China
| | - Weijing Zhang
- Department of Lymphoma, Affiliated Hospital of Academy of Military Medical Science , Beijing, People's Republic of China
| | - Yi Hu
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University , Shanghai, People's Republic of China
| | - Jingkun Pan
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Lei Tian
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Yazuo Hu
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Zhitao Han
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Honghong Zhang
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Xiaoning Wang
- National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric , Beijing, People's Republic of China
| | - Lei Zhao
- Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University, Shanghai, People's Republic of China; National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric, Beijing, People's Republic of China
| |
Collapse
|